skip to Main Content

Ibrutinib Combo Falls Short in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The frontline combination of ibrutinib (Imbruvica) and nab-paclitaxel (Abraxane)/gemcitabine did not show a statistically significant benefit in progression-free or overall survival (OS) versus placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer, according to topline findings of the phase

The full findings of this study will be submitted for presentation at an upcoming medical meeting and/or publication, announced AbbVie, the developer of ibrutinib, in a press release. Read more . . . 

Back To Top